181 related articles for article (PubMed ID: 23552834)
21. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
[TBL] [Abstract][Full Text] [Related]
22. Basic survival needs and access to medicines--coming to grips with TRIPS: conversion + calculation.
Van Puymbroeck RV
J Law Med Ethics; 2010; 38(3):520-49. PubMed ID: 20880239
[TBL] [Abstract][Full Text] [Related]
23. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
[TBL] [Abstract][Full Text] [Related]
24. Canada and access to medicines in developing countries: intellectual property rights first.
Lexchin J
Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
[TBL] [Abstract][Full Text] [Related]
25. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.
Cohen JC; Illingworth P
Dev World Bioeth; 2003 May; 3(1):27-48. PubMed ID: 14577451
[TBL] [Abstract][Full Text] [Related]
26. Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review.
Islam MD; Kaplan WA; Trachtenberg D; Thrasher R; Gallagher KP; Wirtz VJ
Global Health; 2019 Dec; 15(1):88. PubMed ID: 31888688
[TBL] [Abstract][Full Text] [Related]
27. Patent implications in the pharmaceutical industry: Are static high prices leading to dynamic innovations?
Pandey E; Paul SB
Int J Risk Saf Med; 2019; 30(3):179-192. PubMed ID: 31450515
[TBL] [Abstract][Full Text] [Related]
28. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
Babovic S; Wasan KM
J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
[TBL] [Abstract][Full Text] [Related]
29. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
Velasquez G
Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
[TBL] [Abstract][Full Text] [Related]
30. TRIPS and the global pharmaceutical market.
Barton JH
Health Aff (Millwood); 2004; 23(3):146-54. PubMed ID: 15160812
[TBL] [Abstract][Full Text] [Related]
31. Position and enforcement practice of the People's Republic of China's pharmaceutical data exclusivity protection.
Li N; Yu X; Pecht M
Drug Des Devel Ther; 2016; 10():2015-20. PubMed ID: 27382254
[TBL] [Abstract][Full Text] [Related]
32. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
[TBL] [Abstract][Full Text] [Related]
33. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
Pashkov VM; Golovanova IA; Olefir AA
Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
[TBL] [Abstract][Full Text] [Related]
34. Poverty, health & intellectual property rights with special reference to India.
Satyanarayana K; Srivastava S
Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
[TBL] [Abstract][Full Text] [Related]
35. The high price of "free" trade: U.S. trade agreements and access to medicines.
Lopert R; Gleeson D
J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
[TBL] [Abstract][Full Text] [Related]
36. Changes to intellectual property policy in South Africa: putting a stop to evergreening?
Hill JE
Expert Opin Ther Pat; 2014 Aug; 24(8):839-43. PubMed ID: 24965317
[TBL] [Abstract][Full Text] [Related]
37. Intellectual property and access to medicines: an analysis of legislation in Central America.
Cerón A; Godoy AS
Bull World Health Organ; 2009 Oct; 87(10):787-93. PubMed ID: 19876546
[TBL] [Abstract][Full Text] [Related]
38. The Politics and Policies of Regulating Generics in Latin America: A Survey of Seventeen States.
Sweet CM
J Health Polit Policy Law; 2017 Jun; 42(3):485-512. PubMed ID: 28213391
[TBL] [Abstract][Full Text] [Related]
39. [Intellectual property rights and right of access to medicines].
Velásquez G
Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
[TBL] [Abstract][Full Text] [Related]
40. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
